Greenland Mines Ltd (GRML) Stock Price & Analysis
Greenland Mines Ltd (GRML) rose 6.25% to USD 4.76 as of September 8, 2026 at 12:05 UTC, according to Nexqual real-time market data.
GRML last closed at USD 4.76; the session ranged USD 4.39–4.98 on volume of 785,190 shares. Market capitalization is —, with a 52-week range of USD 4.37–37 (NCM). Source: Nexqual, September 8, 2026 at 12:05 UTC.
Key Statistics (as of September 8, 2026 at 12:05 UTC)
| Price | USD 4.76 |
|---|---|
| Change | ▲ 6.25% (up) |
| Previous Close | USD 4.76 |
| Open | USD 4.76 |
| Day Range | USD 4.39 – 4.98 |
| 52-Week Range | USD 4.37 – 37 |
| Volume | 785,190 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (GRML)
Nexqual's technical model rates GRML "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 12:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.69 (neutral) |
| vs SMA50 | Below (USD 9.51) |
| MACD | -1.6 (negative) |
From Greenland Mines Ltd's Latest SEC 10-K Filing (filed 2026-04-01)
Key Strengths & Strategy (as disclosed to the SEC)
- Our cell and gene therapy platform consists of proprietary technology programs (patents issued and pending) that include a gene therapy program that uses a gene therapy approach to produce a therapeutic protein called "Klotho" inside the body to treat neurodegenerative diseases and other diseases of aging (in-licensed pending patent applications from UAB).
Partnerships
- UAB and ICREA reserve the rights to use the licensed rights for internal non-commercial research and to allow other academic institutions to use the licensed rights for internal non-commercial research.    As set forth in the agreement, we are responsible for all costs associated with the research, development, and commercialization of the Products, including entering into a Sponsored Research agreement with Dr. Chillon's and Dr.
- Much of this work will be funded by the Sponsored Research Agreement with UAB in Barcelona.   Supplementation of this human Klotho protein by biologic infusion or by gene therapy may potentially treat many diseases and pathologies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HCTI | Healthcare Triangle, Inc. | USD 0.79 | ▼ 3.57% |
| PLRZ | Polyrizon Ltd. | USD 11.24 | ▼ 10.15% |
| IXHL | Incannex Healthcare Inc. | USD 3.25 | ▼ 0.76% |
| TNON | Tenon Medical, Inc. | USD 3.72 | ▼ 16.78% |
| SMX | SMX (Security Matters) Public L | USD 19.48 | ▲ 20.9% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:05 UTC. This page is informational and not investment advice.